WAYNE, PA — Teleflex Incorporated (NYSE: TFX) is set to host a conference call on October 31, 2024, at 8:00 a.m. Eastern Time to discuss its third quarter financial results and provide an operational update. Participants are required to pre-register for the call to receive dial-in information. The call will also be available via a live audio webcast on Teleflex’s website, with a replay accessible from 11:00 a.m. the same day.
In conjunction with its financial announcements, Teleflex has presented compelling new data on its Barrigel™ rectal spacer at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. Barrigel™, the first and only sculptable hyaluronic acid rectal spacer, is designed to protect the rectum during prostate cancer radiation therapy by significantly reducing radiation exposure to healthy tissue. This innovation is particularly beneficial for patients undergoing hypofractionated treatment regimens, which involve higher radiation doses over fewer sessions.
Jacqueline Welch, Vice President of Global Clinical and Scientific Operations at Teleflex, emphasized the importance of this development: “Building on the safety and efficacy of Barrigel™ rectal spacer previously proven in a randomized clinical trial, the data presented at ASTRO 2024 demonstrate that excellent outcomes can also be achieved in real-world settings and in patients undergoing repeat radiation therapy.”
Welch also highlighted a unique advantage of Barrigel™: “They also show that rare instances of unintended injection regions can be reversed with hyaluronidase, a naturally occurring enzyme. This is an important advantage over other rectal spacers, which cannot be reversed following the initial procedure and require time for biodegradation.”
The adaptability and visibility of Barrigel™ during transrectal ultrasound make it a promising tool in the ongoing effort to enhance patient outcomes and safety in prostate cancer treatment. As prostate cancer diagnoses continue to rise, with approximately 300,000 men in the U.S. affected annually, innovations like Barrigel™ represent significant advancements in treatment options.
Teleflex’s latest research and technological developments highlight its efforts to improve healthcare outcomes for patients with prostate conditions. The conference call and data presentation reflect the company’s dedication to both financial transparency and scientific progress.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.